Unanticipated efficacy of SARS-CoV-2 vaccination in older adults

The rapidity with which vaccines against COVID-19 have been developed and tested is unprecedented. As classically the case with randomized clinical trials, many studies excluded older adults. However, given the early realisation that senior citizens were most highly susceptible to COVID, older indiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Pawelec, Graham, McElhaney, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886644/
https://www.ncbi.nlm.nih.gov/pubmed/33596958
http://dx.doi.org/10.1186/s12979-021-00219-y
_version_ 1783651839727632384
author Pawelec, Graham
McElhaney, Janet
author_facet Pawelec, Graham
McElhaney, Janet
author_sort Pawelec, Graham
collection PubMed
description The rapidity with which vaccines against COVID-19 have been developed and tested is unprecedented. As classically the case with randomized clinical trials, many studies excluded older adults. However, given the early realisation that senior citizens were most highly susceptible to COVID, older individuals have been included in licensing trials under these unusual conditions. The recently published results from the Comirnaty Vaccine (BNT162b) trial unexpectedly documented that vaccine efficacy was equally exceptionally high in older and younger adults. These extremely encouraging trial results with a neoantigen vaccine may suggest the beginning of a paradigm shift in our view of the impact of immunosenescence on vaccination against novel infectious diseases.
format Online
Article
Text
id pubmed-7886644
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78866442021-02-17 Unanticipated efficacy of SARS-CoV-2 vaccination in older adults Pawelec, Graham McElhaney, Janet Immun Ageing Commentary The rapidity with which vaccines against COVID-19 have been developed and tested is unprecedented. As classically the case with randomized clinical trials, many studies excluded older adults. However, given the early realisation that senior citizens were most highly susceptible to COVID, older individuals have been included in licensing trials under these unusual conditions. The recently published results from the Comirnaty Vaccine (BNT162b) trial unexpectedly documented that vaccine efficacy was equally exceptionally high in older and younger adults. These extremely encouraging trial results with a neoantigen vaccine may suggest the beginning of a paradigm shift in our view of the impact of immunosenescence on vaccination against novel infectious diseases. BioMed Central 2021-02-17 /pmc/articles/PMC7886644/ /pubmed/33596958 http://dx.doi.org/10.1186/s12979-021-00219-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Commentary
Pawelec, Graham
McElhaney, Janet
Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
title Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
title_full Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
title_fullStr Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
title_full_unstemmed Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
title_short Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
title_sort unanticipated efficacy of sars-cov-2 vaccination in older adults
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886644/
https://www.ncbi.nlm.nih.gov/pubmed/33596958
http://dx.doi.org/10.1186/s12979-021-00219-y
work_keys_str_mv AT pawelecgraham unanticipatedefficacyofsarscov2vaccinationinolderadults
AT mcelhaneyjanet unanticipatedefficacyofsarscov2vaccinationinolderadults

Ejemplares similares